TEVIMBRA
GrowthmAbBLAINJECTIONINJECTABLE
Approved
Mar 2025
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TEVIMBRA is pd-1 ligands pd-l1 and pd-l2, to the pd-1 receptor found on t cells, inhibits t-cell proliferation and cytokine production. Approved for metastatic esophageal squamous cell carcinoma (escc) after prior systemic chemotherapy. First approved in 2025.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEVIMBRA is a monoclonal antibody (mAb) therapeutic approved by FDA on March 3, 2025, via BLA (Biologics License Application). The specific indication(s), mechanism of action, and target patient population have not yet been disclosed in public filings. As an injectable biologic in growth-stage lifecycle, TEVIMBRA represents an emerging franchise with significant development runway.
Growth
Early-stage growth asset with 6 linked career opportunities indicates active team building; commercial infrastructure development underway with competitive pressure at moderate 30% intensity suggesting defensible market position.
Mechanism of Action
PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.